Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Integral Diagnostics Ltd. ( (AU:IDX) ).
Integral Diagnostics Ltd. has been served with a legal claim by the Vendors of the Imaging Queensland business, which it acquired in 2019. The Vendors are seeking damages related to an earn-out valuation dispute, which was previously determined by an independent expert to be $2.2 million. Despite efforts by Integral to resolve the issue based on this valuation, the Vendors have initiated legal proceedings. Integral plans to defend itself in this litigation, which could have implications for its financial provisioning and stakeholder relations.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand, employing some of Australasia’s leading radiologists and diagnostic imaging specialists. The company operates under a unique medical leadership model that emphasizes quality patient care, service, and access.
Average Trading Volume: 1,280,900
Technical Sentiment Signal: Buy
Current Market Cap: A$990.7M
For a thorough assessment of IDX stock, go to TipRanks’ Stock Analysis page.